HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

An over-the-counter moisturizer is as clinically effective as, and more cost-effective than, prescription barrier creams in the treatment of children with mild-to-moderate atopic dermatitis: a randomized, controlled trial.

AbstractBACKGROUND:
Atopic dermatitis (AD) is a prevalent skin disorder with significant cost of treatment. Several prescription device moisturizers have been approved by the FDA to treat AD but are significantly more expensive than well-crafted over-the-counter (OTC) moisturizers. No studies have been performed to compare both the clinical efficacy and cost-efficacy of these prescription devices to OTC moisturizers.
PURPOSE:
The purpose of this study is to compare the clinical efficacy and cost-efficacy of a glycyrrhetinic acid-containing barrier repair cream (BRC-Gly, Atopiclair®), a ceramide-dominant barrier repair cream (BRC-Cer, EpiCeram®) and an OTC petroleum-based skin protectant moisturizer (OTC-Pet, Aquaphor Healing Ointment®) as monotherapy for mild-to-moderate AD in children.
METHODS:
Thirty-nine patients, age 2-17 years, with mild-to-moderate AD were randomized 1:1:1 to receive one of three treatments-BRC-Gly, BRC-Cer or OTC-Pet-with instructions to apply the treatment three times daily for three weeks. Disease severity and improvement was assessed at baseline and on days 7 and 21.
RESULTS:
No statistically significant difference for any efficacy assessment was found between the three groups at each time point. The OTC-Pet was found to be at least 47 times more cost-effective than BRC-Gly or BRC-Cer.
LIMITATIONS:
The relatively small sample size of 39 subjects was not sufficient to establish OTC-Pet as superior treatment in AD.
CONCLUSIONS:
OTC-Pet is as effective in treating mild-to-moderate AD as both BRC-Gly and BRC-Cer and is at least 47 times more cost-effective.
NAME OF REGISTRY:
II-AF-ATD-Aquaphor, Comparing the Efficacy and Cost-Effectiveness of Aquaphor to Atopiclair and EpiCeram in Children with Mild to Moderate Atopic Dermatitis. REGISTRATION IDENTIFIER: NCT01093469.
AuthorsDrew W Miller, Sarah B Koch, Brad A Yentzer, Adele R Clark, Jenna R O'Neill, Julie Fountain, Teresa M Weber, Alan B Fleischer Jr
JournalJournal of drugs in dermatology : JDD (J Drugs Dermatol) Vol. 10 Issue 5 Pg. 531-7 (May 2011) ISSN: 1545-9616 [Print] United States
PMID21533301 (Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial)
Chemical References
  • Ceramides
  • Dermatologic Agents
  • Dietary Fats
  • Drug Combinations
  • Emollients
  • EpiCeram
  • Fatty Acids
  • MAS063DP
  • Nonprescription Drugs
  • Plant Extracts
  • Prescription Drugs
  • Petrolatum
  • Cholesterol
  • Glycyrrhetinic Acid
Topics
  • Administration, Cutaneous
  • Adolescent
  • Ceramides (administration & dosage, economics, therapeutic use)
  • Child
  • Child, Preschool
  • Cholesterol (administration & dosage, economics, therapeutic use)
  • Cost-Benefit Analysis
  • Dermatitis, Atopic (drug therapy, pathology)
  • Dermatologic Agents (administration & dosage, economics, therapeutic use)
  • Dietary Fats (administration & dosage, economics, therapeutic use)
  • Double-Blind Method
  • Drug Combinations
  • Emollients (administration & dosage, economics, therapeutic use)
  • Fatty Acids (administration & dosage, economics, therapeutic use)
  • Female
  • Glycyrrhetinic Acid (administration & dosage, economics, therapeutic use)
  • Humans
  • Male
  • Nonprescription Drugs (administration & dosage, economics, therapeutic use)
  • Petrolatum (administration & dosage, economics, therapeutic use)
  • Plant Extracts (administration & dosage, economics, therapeutic use)
  • Prescription Drugs (administration & dosage, economics, therapeutic use)
  • Severity of Illness Index
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: